 Histone-Lysine N-Methyltransferase
"Histone-Lysine N-Methyltransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the methylation of the epsilon-amino group of lysine residues in proteins to yield epsilon mono-, di-, and trimethyllysine. EC 2.1.1.43.
| Descriptor ID |
D011495
|
| MeSH Number(s) |
D08.811.913.555.500.800.400
|
| Concept/Terms |
Histone-Lysine N-Methyltransferase- Histone-Lysine N-Methyltransferase
- Histone Lysine N Methyltransferase
- N-Methyltransferase, Histone-Lysine
- Protein Methylase III
- Histone-Lysine Methyltransferase
- Histone Lysine Methyltransferase
- Methyltransferase, Histone-Lysine
- Protein Lysine Methyltransferase
- Methyltransferase, Protein Lysine
- Protein Methyltransferase III
|
Below are MeSH descriptors whose meaning is more general than "Histone-Lysine N-Methyltransferase".
Below are MeSH descriptors whose meaning is more specific than "Histone-Lysine N-Methyltransferase".
This graph shows the total number of publications written about "Histone-Lysine N-Methyltransferase" by people in UAMS Profiles by year, and whether "Histone-Lysine N-Methyltransferase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 0 | 1 | 1 | | 2020 | 1 | 1 | 2 | | 2019 | 0 | 1 | 1 | | 2016 | 2 | 2 | 4 | | 2015 | 0 | 1 | 1 | | 2014 | 3 | 2 | 5 | | 2013 | 0 | 2 | 2 | | 2012 | 2 | 1 | 3 | | 2011 | 1 | 1 | 2 | | 2010 | 5 | 0 | 5 | | 2009 | 2 | 1 | 3 | | 2008 | 4 | 0 | 4 | | 2007 | 0 | 1 | 1 | | 2006 | 2 | 0 | 2 | | 2005 | 1 | 1 | 2 | | 2003 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Histone-Lysine N-Methyltransferase" by people in Profiles over the past ten years.
-
Fenu EM, O'Neill SS, Insuasti-Beltran G, Pettenati MJ, Giffen M, Harrison WT. Sudden Unexpected Death in a Child From Acute Myeloid Leukemia. Am J Forensic Med Pathol. 2021 Jun 01; 42(2):174-177.
-
El Jamal SM, Salama A, Marcellino BK, Abulsayen HA, Zhou X, Hassan M, Firpo-Betancourt A, Saad AG. Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical Characteristics With KMT2A (MLL) Gene Rearrangement Correlation. Appl Immunohistochem Mol Morphol. 2020 08; 28(7):501-507.
-
Dong C, West KL, Tan XY, Li J, Ishibashi T, Yu CH, Sy SMH, Leung JWC, Huen MSY. Screen identifies DYRK1B network as mediator of transcription repression on damaged chromatin. Proc Natl Acad Sci U S A. 2020 07 21; 117(29):17019-17030.
-
Mousavian Z, Nowzari-Dalini A, Rahmatallah Y, Masoudi-Nejad A. Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia. Mol Med. 2019 08 01; 25(1):36.
-
Kim HS, Williamson EA, Nickoloff JA, Hromas RA, Lee SH. Metnase Mediates Loading of Exonuclease 1 onto Single Strand Overhang DNA for End Resection at Stalled Replication Forks. J Biol Chem. 2017 01 27; 292(4):1414-1425.
-
Mousavian Z, Nowzari-Dalini A, Stam RW, Rahmatallah Y, Masoudi-Nejad A. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia. Cell Oncol (Dordr). 2017 Feb; 40(1):33-45.
-
Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5783-5794.
-
Wu SP, Pfeiffer RM, Ahn IE, Mailankody S, Sonneveld P, van Duin M, Munshi NC, Walker BA, Morgan G, Landgren O. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. Clin Cancer Res. 2016 Aug 15; 22(16):4039-44.
-
Nakshatri H, Appaiah HN, Anjanappa M, Gilley D, Tanaka H, Badve S, Crooks PA, Mathews W, Sweeney C, Bhat-Nakshatri P. NF-?B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death Dis. 2015 Jan 22; 6:e1608.
-
Campbell CL, Collins RT, Zarate YA. Severe neonatal presentation of Kleefstra syndrome in a patient with hypoplastic left heart syndrome and 9q34.3 microdeletion. Birth Defects Res A Clin Mol Teratol. 2014 Dec; 100(12):985-90.
-
Papazyan R, Voronina E, Chapman JR, Luperchio TR, Gilbert TM, Meier E, Mackintosh SG, Shabanowitz J, Tackett AJ, Reddy KL, Coyne RS, Hunt DF, Liu Y, Taverna SD. Methylation of histone H3K23 blocks DNA damage in pericentric heterochromatin during meiosis. Elife. 2014 Aug 26; 3:e02996.
-
Mirabella F, Murison A, Aronson LI, Wardell CP, Thompson AJ, Hanrahan SJ, Fok JH, Pawlyn C, Kaiser MF, Walker BA, Davies FE, Morgan GJ. A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. PLoS One. 2014; 9(6):e99493.
-
Pawlyn C, Kaiser MF, Davies FE, Morgan GJ. Current and potential epigenetic targets in multiple myeloma. Epigenomics. 2014 Apr; 6(2):215-28.
-
Conti Ad, Kobets T, Escudero-Lourdes C, Montgomery B, Tryndyak V, Beland FA, Doerge DR, Pogribny IP. Dose- and time-dependent epigenetic changes in the livers of Fisher 344 rats exposed to furan. Toxicol Sci. 2014 Jun; 139(2):371-80.
-
Chappell G, Kutanzi K, Uehara T, Tryndyak V, Hong HH, Hoenerhoff M, Beland FA, Rusyn I, Pogribny IP. Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. Int J Cancer. 2014 Jun 15; 134(12):2778-88.
-
Pogribny IP, Tryndyak VP, Pogribna M, Shpyleva S, Surratt G, Gamboa da Costa G, Beland FA. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents. Int J Oncol. 2013 May; 42(5):1822-32.
-
Simpson NE, Tryndyak VP, Pogribna M, Beland FA, Pogribny IP. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics. 2012 Dec 01; 7(12):1413-20.
-
Williamson EA, Damiani L, Leitao A, Hu C, Hathaway H, Oprea T, Sklar L, Shaheen M, Bauman J, Wang W, Nickoloff JA, Lee SH, Hromas R. Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy. Cancer Res. 2012 Dec 01; 72(23):6200-8.
-
Hromas R, Williamson EA, Fnu S, Lee YJ, Park SJ, Beck BD, You JS, Leitao A, Laitao A, Nickoloff JA, Lee SH. Chk1 phosphorylation of Metnase enhances DNA repair but inhibits replication fork restart. Oncogene. 2012 Sep 20; 31(38):4245-54.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|